Insider Selling: Kura Oncology (NASDAQ:KURA) Insider Sells $179,220.60 in Stock

Posted by Stanley Muller on Oct 2nd, 2026

Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) insider Brian Powl sold 17,020 shares of the company’s stock in a transaction dated Monday, September 28th. The shares were sold at an average price of $10.53, for a total transaction of $179,220.60. Following the completion of the sale, the insider directly owned 152,249 shares in the company, valued at approximately $1,603,181.97. The trade was a 10.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Kura Oncology Trading Down 0.6%

Shares of NASDAQ:KURA opened at $10.65 on Friday. Kura Oncology, Inc. has a 52-week low of $7.36 and a 52-week high of $13.90. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73. The company has a market capitalization of $947.42 million, a P/E ratio of -3.16 and a beta of 0.47. The company has a 50-day simple moving average of $11.23 and a 200 day simple moving average of $10.19.

Kura Oncology (NASDAQ:KURA – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.11. The firm had revenue of $20.87 million for the quarter, compared to the consensus estimate of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. Sell-side analysts forecast that Kura Oncology, Inc. will post -3.25 earnings per share for the current year.

Kura Oncology News Summary

Here are the key news stories impacting Kura Oncology this week:

Positive Sentiment: JPMorgan initiated coverage of Kura Oncology with an “overweight” rating and a $30 price target, implying substantial upside from recent trading levels. The firm views Kura as a promising precision-cancer-medicine developer, particularly because of its menin-inhibitor platform and lead program, ziftomenib, for genetically defined acute myeloid leukemia. JPMorgan Kura Oncology rating article
Positive Sentiment: CNBC highlighted JPMorgan’s view that KURA could nearly triple, reinforcing the potential valuation impact of successful clinical and regulatory execution. The bullish outlook is particularly important for a biotechnology stock trading below the average analyst target of approximately $25.40. CNBC Kura Oncology analyst outlook
Neutral Sentiment: Kura’s financial position remains relatively liquid, with a reported quick ratio of 4.71 and current ratio of 4.73, but the company remains unprofitable and analysts expect a significant full-year loss. That means the stock’s valuation continues to depend heavily on clinical progress rather than current earnings.
Negative Sentiment: Multiple insiders, including executives Kathleen Ford, Brian Powl, Mollie Leoni, Thomas Doyle and Teresa Bair, sold shares in late September and October 1. The reported transactions represent roughly 97,000 shares and more than $1 million in proceeds, creating a potential near-term overhang. The sales do not necessarily indicate deteriorating business prospects, since the insiders retained meaningful holdings, but they may weigh on investor confidence. Kura Oncology insider sales

Institutional Trading of Kura Oncology

Institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in Kura Oncology during the 2nd quarter worth $115,286,000. Armistice Capital LLC lifted its holdings in shares of Kura Oncology by 5.7% during the fourth quarter. Armistice Capital LLC now owns 4,936,000 shares of the company’s stock worth $51,285,000 after buying an additional 264,000 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Kura Oncology by 32.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock valued at $11,591,000 after acquiring an additional 348,127 shares during the period. Bank of America Corp DE boosted its position in shares of Kura Oncology by 46.1% in the first quarter. Bank of America Corp DE now owns 1,230,131 shares of the company’s stock valued at $10,001,000 after acquiring an additional 388,003 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Kura Oncology in the second quarter valued at about $10,927,000.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on KURA shares. Wedbush increased their price target on Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a research note on Thursday, August 13th. Citizens Jmp reissued a “market outperform” rating and issued a $24.00 price objective on shares of Kura Oncology in a research report on Monday, August 24th. JPMorgan Chase & Co. started coverage on shares of Kura Oncology in a research report on Thursday. They issued an “overweight” rating and a $30.00 price objective on the stock. Morgan Stanley set a $24.00 target price on shares of Kura Oncology in a research note on Monday, August 24th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a report on Monday, August 24th. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $25.69.

Read Our Latest Stock Analysis on Kura Oncology

Kura Oncology Company Profile

(Get Free Report)

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.

Kura’s leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.